The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...

That might be a good commercial strategy, but it also looks like an admission that the threat from compounders is here to stay. Lilly shares were down 1.3% Wednesday. The price of the Zepbound ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

However, it looks like the stock is back on investors’ radar with the latest positive Zepbound data. Let’s understand the company’s strengths and weaknesses to better analyze how to play the ...

Zepbound's sales were already growing fast ... had predicted a 25% mean weight loss for CagriSema, but it still looks like the company has a better product on its hands. CagriSema is just one ...